CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
26.49
+1.54 (6.17%)
At close: Aug 13, 2025, 4:00 PM
25.40
-1.09 (-4.11%)
Pre-market: Aug 14, 2025, 9:11 AM EDT
CG Oncology Employees
CG Oncology had 113 employees as of December 31, 2024. The number of employees increased by 52 or 85.25% compared to the previous year.
Employees
113
Change (1Y)
52
Growth (1Y)
85.25%
Revenue / Employee
$4,876
Profits / Employee
-$1,133,460
Market Cap
2.02B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 113 | 52 | 85.25% |
| Dec 31, 2023 | 61 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CGON News
- 6 days ago - CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 weeks ago - CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade) - Seeking Alpha
- 2 months ago - CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why - Benzinga
- 3 months ago - CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting - GlobeNewsWire
- 4 months ago - CG Oncology Looks Attractive At Current Prices (Rating Upgrade) - Seeking Alpha
- 5 months ago - Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy - GlobeNewsWire